Summary: During intensive care, the severity of gut-derived systemic endotoxaemia in 16 patients with active Crohn's disease was characterized by the simultaneous determination of elastase/ai-proteinase-inhibitor and L/ww/ws-amoebocyte-lysate-reactivity. Using both assays in 15/16 patients the detectable endotoxic activity during the disease course was reflected by a parallelism between elastase/a r proteinase-inhibitor and Limulusamoebocyte-lysate-reactivity. In 8 gut-irrigated patients, significantly lower elastase/a r proteinase-inhibitor concentrations and L/wi//i/,s-amoebocyte-lysate-reactivities were measured compared with 8 gut-nonirrigated patients. The Crohn's disease activity index and the van Hees activity index as well as the inpatient time were significantly lower in lavage patients compared with gut-nonirrigated patients. It is concluded with that elastase/arproteinase-inhibitor can be used as an alternative to the bioassayed L/mw/w^-amoebocyte-lysatereactivity in order to characterize systemic endotoxaemia.
Introduction
In patients with Crohn's disease, the Grä/w-negative enterobacteriaceae (Escherichia coli f Salmonella, Proteus, Klebsiella, Enterobacter, Serratia, Yersinid) as well as their cell wall constituents, the lipopolysac* charides (endotoxin), contribute to the inflammatory lesions in the bowel wall (1) . These are mainly caused by abnormal and invasive bacterial colonisation (2 -6) . During the acute phase of Crohn's disease, a systemic endotoxaemia (7-* 10) and elevated antibody concentrations directed against Escherichia coli-O serotypes (11, 12) , and lipid A (13 -15) , the toxophor within the lipopolysaccharide molecule (16) , were found.
Endotoxin induces the release of elastase and other inflammation triggering substances (cathepsin, collagenase, myeloperoxidase) from mononuclear phagocytes (17, 18) . The proteolytic inflammatory effect of elastase is generated when the amount of ai-proteinase-inhibitor does not suffice to neutralize the elastase activity (19) .
Lipopolysaccharides also induce a leukocytosis in patients with Crohn's disease (20, 21) concomitantly with a neutrophilia and a lymphocytopenia (22, 23) . In the damaged bowel wall a massive infiltration of granulocyteSj macrqphages, cytotoxic-T-cells, B-and plasma-cells was shown (24) (25) (26) .
Based upon these inter-related features it was of interest to determine elastase/a r proteinase-inhibitor in plasma of lipopolysaccharide-stimulated whole blood from healthy adults and patients with Crohn's disease. The extent of endotoxaemia in lavage and gut-nonirrigated patients (27) with active Crohn's disease was characterized by the simultaneous application of the turbidimetric L/raM/itf-amoebocyte-lysate-reactivity test (28, 29) and the elastase/tti-proteinase-inhibitor enzyme-linked-immunosorbent assay (30, 31) as well as by the Crohn's disease activity index (32) and the van Hees activity index (33).
Materials and Methods

Specimens
From 16 patients (male/female ratio: 7/9, age range: 17-48 years), with active Crohrfs disease confirmed by clinical, radiological, endoscopic and pathohistological features, the course of endotoxaemia was assayed during 14 days of inpatient time. All patients were administered total parenteral nutrition, 9620 kJ/24 h in a volume of 2500 ml through a central venous catheter at the day of admission for at least one week. As a standard therapeutic regimen prednisone and sulphasalazine were given orally to all patients.
For 8 lavage patients, 2 whole gut-irrigations were performed by placing a radiopaque polyvinyl tube into the jejunum (34). NaCl solution (0.15 mol/1) containing 5-acetyl-salicylic acid was used as lavage fluid at 37 °C in the first week (27) .
Serum sodium, potassium, bicarbonate, haemoglobin, haematocrit and body weight were determined before, during and after whole gut-irrigation. For randomisation, cards were prepared, which indicated to which treatment group the patients were allocated. 8/16 patients allocated to the lavage group gave informed consent before treatment.
From a 59 year-old intensive care patient samples were drawn in 2 h intervals to study the 24 h-profile between elastase/ar proteinase-inhibitor and L/ww/wi-amoebocyte-lysate-reactivity.
Fifty clinically apparent healthy adults (male/female ratio: 23/27, age range: 18-64 years), who were routinely examined by the personnel medical service, served to set up a reference range for elastase/a r proteinase-inhibitor. Laboratory data for these individuals based on haemogram (erythrocyte and leukocyte count, haemoglobin, haematocrit), aspartate aminotransferase, alanine aminotransferase, serum creatinine, urea, hepatitis B surface antigen, anti-hepatitis B surface antibody showed normal values in all cases. To test the influence of various anticoagulants on the elastase/ a r proteinase-inhibitor assay, whole blood from 10 healthy adults was anticoagulated either with heparin, or K 2 -EDTA, 0.24 mol/1 (cat. No. 03258) or citrate, 0.1 mol/1 (cat. No. 05.268, Sarstedt, D-5223 N mbrecht). After different storage times (10 min, 30 min, 60 min) and incubation temperatures (4 °C, 20 °C, 37 °C) the elastase/a^proteinase inhibitor content in plasma was assayed.
To test the release of elastase into plasma from unstimulated and lipopolysaccharide-stimulated whole blood, additional samples from 10 healthy adults and 5 patients with untreated active Crohrfs disease were obtained. After incubation with 20 μg of lipopolysaccharide (lipopolysaccharide from Escherichia coli 055:B5, lot. No. 3120 Difco-Lab., Detroit, USA) for 30 min at 37 °C elastase/a,-proteinase-inhibitor was determined in plasma.
Elastase/dt-proteinase-inhibitor assay
The elastase/ctt-proteinase-inhibitor assay (lot. No. 41292105), standards (1 μg/l, 2 μg/l, 4.5 jig/1,11.9 μ §/1) as well as the human control plasmas (106 μg/l, 153 μg/l) were kindly supplied by Dr. S. Neumann (Biochemische Forschung Merck, D^6100 Darmstadt). The working procedure of the elastase/arproteinase-inhibitor assay was performed unmodified as described elsewhere (30, 31 
Statistical analysis
For evaluation of results imprecision within-nm and betweend ays, Student's t-test (p < 0.025), multi-variate variation analysis (p < 0.05), coefficient of correlation (r) and Spearmarfs coefficient of rank correlation (rs) were performed as described elsewhere (36).
Results
Effect of various anticoagulants, storage times and temperatures on elastase/c^-proteinase-inhibitor
No significantly different (p > 0.05) elastase/cti-prot einase-infaibitor concentrations were found in plasma from heparinized, K 2 -EDTA-or citrate-containing whole blood samples, stored for 10, 30 or 60 min at 4°C or 20 °C (tab. 1). In contrast, a significantly (p < 0.01) elevated elastase/ctrproteinase inhibitor concentration was determined in plasma from whole blood stored 60 min compared with 10« min or 30 min, at 37 °C.
Elastase/c^-proteinase-inhibitor in plasma of lipopolysaccharide-stimulated whole blood
Increased plasma elastase/arproteinase-inhibitor (p < 0.0005) was found in lipopolysaccharide-stimulated whole blood (patients with CroHn's disease: 1154.6 ± 157.3 μ^ healthy adults: 231.5 ± 74.6 μg/l) compared with unstimulated whole blood (pat ients rt with Crohn's disease: 478.0 ±162.5 μg/l; healthy adults: 92.1 ± 14.0 μg/l). ., Table l . Plasma-elastase/arproteinase-inhibitor in whole blood samples (n = 10) from healthy adults containing various anticoagulants and treated with different storage times and incubation temperatures (x = mean value, s = 1 standard deviation). /1-A parallel course (r = 0.79) between elastase/ cti-proteinase-inhibitor and positive Limulus-amoebocyte-lysate reactivities was found.
The same parallelism (0.68 > r < 0.99; 0.60 > rs < 1.00) between elastase/cti-proteinase-inhibitor and Lf'mw/ws-amoebocyte-lysate-reactivity was found for 15/16 lavage-and gut^nonirrigated patients with Crohn's disease. Two representative courses are depicted in figure 1 and 2.
Lavage patients revealed significantly lower (p < 0.025) mean values of elastase/a^proteinase-inhibitor and Lz/ww/M^amoebocyte-lysate-reactivity at day 6 and 8 than gut-nonirrigated patients ( figs. 3, 4) . In accordance with the course of elastase/arproteinaseinhibitor and jL/WM/wj'-amoebocyte-lysate-reactivity, the Crohn's disease activity index and van Hees index decreased more rapidly (p < 0.025) in the lavage group (Crohn's disease activity index: 228 ± 39 index points to 86 ± 42 index points; van Hees: 214 ± 33 index points to 157 ± 33 index points) than in gutnonirrigated patients (Crohn's disease activity index: 240 + 46 index points to 158 ± 53 index points; van Hees: 233 ± 46 index points to 191 ± 28 index points). Patients from the lavage group (25.2 ± 8.5 days) were discharged earlier from the hospital than gut-nonirrigated patients (39.1 ±11.9 days) (p < 0.01).
Discussion
In patients with active inflammatory bowel disease and intestinal mucosal lesions the enteral resorption of lipopolysaccharides results in portal endotoxaemia (37), due to insufficient clearance of lipopolysaccharides by the hepatic mononuclear phagocytic system (38, 39). Endotoxin may also reach the blood stream by transmural escape through the peritoneal cavity or propagation via intestinal lymphatics and the ductus thoracicus (8) .
A systemic endotoxaemia based on single determinations of positive L/mw/w^-amoebocyte-lysate-reactivity was found in all patients with active Crohn's disease (8, 9) . In contrast, Kruis et al. (14) detected a positive L/raw/itf-amoebocyte-lysate-reactivity only in a minority of patients. The cause of the above mentioned discrepancy may be the interference of Limu-Λ/j-amoebocyte-lysate-reactivity, with polynucleotides, peptidoglycans derived from cell walls of Grampositive bacteria, plasma macromolecules (HDL, phospholipides, inhibitors) and leukocytic factor(s) (28, 29) as well as Lfww/w^-amoebocyte-lysate-batch variabilities. Thus, single determinations of Limulusamoebocyte-lysate-reactivity are of limited clinical validity in characterizing "endotoxaemia" (29). Therefore, replicate determinations of the LzAww/w^-amoebocyte-lysate-reactivity were performed in order to monitor the patient-specific course of endotoxaemia.
Lipopolysaccharides also effect the release of elastase from leukocytes (18, 19) . Free elastase amplifies the inflammatory potency of lipopolysaccharides (21, 40) by cleavage of clotting-, complement-and fibrinolyticfactors, immunoglobulins, transport proteins and plasma protein inhibitors (41 -47) as well as by destruction of collagen, elastin and proteoglycans (48). Elastase/cti-proteinase-inhibitor Lzmw/wi-arnoebocyte-lysate-reactivity
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Based upon this pathochemical interrelationship, L/ww/ws-amoebocyte-lysate-reactivity and elastase/ttiproteinase-inhibitor were determined in parallel to characterize the course of endotoxaemia.
The precision data (n = lOKorelastase/ai-proteinaseinhibitor (coefficients of variation: imprecision withinrun 3.6%; imprecision between-days 9.0%) and the obtained reference range (95% percentile: < 106 were in accordance with other authors (30, 31, 49). The practicability (e. g. influence of anticoagulants, storage-and temperature conditions) of the elastase/ a a -proteinase-inhibitor assay showed that in heparin-K 2 -EDTA-or citrate-containing plasma, similar elastase/ai-proteinase-inhibitor concentrations were detectable. These findings were the prerequisite for using To confirm the in vitro findings, elastase/a r proteinase-inhibitor and Limw/M,s-amoebocyte-lysate-reactivity were determined in a septic intensive care patient with an Escherichia colt bacteraemia. The observed parallel profile between elastase/a^proteinase-inhibitor and Lzmw/wj-amoebocyte-lysate-reactivity for this patient and the patient with active Crohn's disease suggest that although different analytes were determined, both tests measured the underlying endotoxic activity simultaneously in a similar manner. Elastase/ ai-proteinase-inhibitor seemed to be a more adequate marker for the inflammatory disease activity than the leukogram, since in the bacteraemic septic patient with leukocyte values within the reference range, elastase/arproteinase-inhibitor levels were found to be constantly elevated.
The constantly lower elastase/aj-proteinase-inhibitor concentrations and L/ww/w^-amoebocyte-lysate-reactivities as well as the more rapid reduction of endotoxic activity in lavage patients, compared with gutnonirrigated patients, support the hypothesis that the reduced endotoxaemia in lavage patients was due to a reduction of intestinal lipopolysaccharide biomass.
In agreement with our findings a reduction of intestinal bacterial flora was also reported by Hewitt et al.
(52) after lavage treatment. The difference of endotoxic activity in lavage-and gut-nonirrigated patients was not the result of a dilution effect by the orthograde saline gut-irrigation, since serum sodium, potassium, bicarbonate, haematocrit, haemoglobin and body weight were stable before, during and after whole gut-irrigation.
In agreement with our results, Adeyemi et al. (53) found, in patients with active Crohn's disease, elevated elastase/tti-proteinase-inhibitor compared with healthy adults and patients with inactive Crohn's disease. Their results yielded a positive correlation between the elastase/ai-proteinase-inhibitor and the Crohn's disease activity index. In conclusion the longitudinal study showed that a) elastase/aj-proteinase-inhibitor may be used as an alternative to the Z,/w«/t/s-amoebocyte-lysate-reactivity and b) both tests as well as the Crohn's disease activity index and van Hees activity index yielded a lower degree of endotoxaemia and a reduced inpatient time in lavage patients, compared with gut-nonirrigated patients.
